コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 sks of these therapies, such as the risk for progressive multifocal leukoencephalopathy.
2 iformly fatal demyelinating disease known as progressive multifocal leukoencephalopathy.
3 ortunately been implicated in three cases of progressive multifocal leukoencephalopathy.
4 he risk of serious adverse events, including progressive multifocal leukoencephalopathy.
5 tral nervous system (CNS) in humans known as progressive multifocal leukoencephalopathy.
6 nists may thus be useful in the treatment of progressive multifocal leukoencephalopathy.
7 may lead to new forms of immunotherapies for progressive multifocal leukoencephalopathy.
8 y progressing demyelinating disease known as progressive multifocal leukoencephalopathy.
9 s with the JCV-induced demyelinating disease progressive multifocal leukoencephalopathy.
10 central nervous system demyelinating disease progressive multifocal leukoencephalopathy.
11 ith multiple sclerosis, those susceptible to progressive multifocal leukoencephalopathy.
12 ubacute, debilitating demyelinating disease, progressive multifocal leukoencephalopathy.
13 talizumab switch to other therapies to avoid progressive multifocal leukoencephalopathy.
14 the brain, causing a demyelinating disease, progressive multifocal leukoencephalopathy.
15 susceptible to lytic infection, resulting in progressive multifocal leukoencephalopathy.
16 One patient died of progressive multifocal leukoencephalopathy.
17 s not changed in the brains of patients with progressive multifocal leukoencephalopathy.
18 been limited by its association with risk of progressive multifocal leukoencephalopathy.
19 the mechanism of natalizumab treatment with progressive multifocal leukoencephalopathy.
20 tment of other cases of immunodeficiency and progressive multifocal leukoencephalopathy.
21 nce imaging-detected lesions consistent with progressive multifocal leukoencephalopathy.
22 ions of elevated perfusion within lesions of progressive multifocal leukoencephalopathy.
23 e herpesvirus infections and potentially for progressive multifocal leukoencephalopathy.
24 alizumab recipients were diagnosed as having progressive multifocal leukoencephalopathy.
25 anticipated life threatening adverse effect: progressive multifocal leukoencephalopathy.
26 d not observe JC viremia, JC nephropathy, or progressive multifocal leukoencephalopathy.
27 the central nervous system, where it causes progressive multifocal leukoencephalopathy.
28 /isosporiasis, 90% and infinite (1.61/0.00); progressive multifocal leukoencephalopathy, 87% and 19 (
29 lyomavirus, JCPyV, is the causative agent of progressive multifocal leukoencephalopathy, a rare demye
32 yomavirus JC (JCV) is the causative agent of progressive multifocal leukoencephalopathy and of JCV gr
33 the ofatumumab group (the most common being progressive multifocal leukoencephalopathy and pneumonia
34 e clinical and pathological presentations of progressive multifocal leukoencephalopathy, and advances
35 Hodgkin lymphoma, M. tuberculosis infection, progressive multifocal leukoencephalopathy, and cryptosp
36 y have shed new light on the pathogenesis of progressive multifocal leukoencephalopathy, and on its p
37 al leukoencephalopathy, our understanding of progressive multifocal leukoencephalopathy, and the mech
39 a patient treated with natalizumab died from progressive multifocal leukoencephalopathy, associated w
40 ous events were notified except 1 death from progressive multifocal leukoencephalopathy at month 4.
41 phages and activated microglia in stroke and progressive multifocal leukoencephalopathy, but not expr
42 ures and patients can be risk stratified for progressive multifocal leukoencephalopathy by testing fo
44 central nervous system disease analogous to progressive multifocal leukoencephalopathy caused by Joh
45 lizumab discontinuation, 1 patient developed progressive multifocal leukoencephalopathy during the ob
47 nating syndromes (including cases resembling progressive multifocal leukoencephalopathy) have been re
48 ion of Purkinje cells and absence of classic progressive multifocal leukoencephalopathy histopatholog
49 95% confidence interval [CI], 2.98-8.87) and progressive multifocal leukoencephalopathy (HR, 4.22; 95
50 CV) causes the central demyelinating disease progressive multifocal leukoencephalopathy in about 5% o
51 therapy has changed the clinical spectrum of progressive multifocal leukoencephalopathy in HIV-infect
52 ive agent of the rare demyelinating disease, progressive multifocal leukoencephalopathy in immunocomp
53 JCV, causes the fatal demyelinating disease progressive multifocal leukoencephalopathy in immunocomp
54 gic agent of the fatal demyelinating disease progressive multifocal leukoencephalopathy in immunocomp
56 CV) may lead to development of demyelinating progressive multifocal leukoencephalopathy in patients w
57 to determine what led to the development of progressive multifocal leukoencephalopathy in the natali
63 nts should be considered only if the risk of progressive multifocal leukoencephalopathy is high and o
65 ype virus first isolated from a patient with progressive multifocal leukoencephalopathy, is character
67 sought to characterize perfusion patterns of progressive multifocal leukoencephalopathy lesions by ar
68 nse hyperperfusion within and at the edge of progressive multifocal leukoencephalopathy lesions in a
71 logies with prominent myelin injury, namely, progressive multifocal leukoencephalopathy, metachromati
77 s, the three cases of natalizumab-associated progressive multifocal leukoencephalopathy, our understa
78 and the evolution of JC polyomavirus-induced progressive multifocal leukoencephalopathy over three di
80 ncipal target of JCV productive infection in progressive multifocal leukoencephalopathy patients, lit
81 e been associated with prolonged survival in progressive multifocal leukoencephalopathy patients.
82 psing-remitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PML) after h
83 nd 1 with rheumatoid arthritis who developed progressive multifocal leukoencephalopathy (PML) after r
84 ed with a favorable outcome in patients with progressive multifocal leukoencephalopathy (PML) and cro
85 course of patients with natalizumab-related progressive multifocal leukoencephalopathy (PML) and ful
86 frequently fatal demyelinating brain disease progressive multifocal leukoencephalopathy (PML) carry s
88 patients with multiple sclerosis who develop progressive multifocal leukoencephalopathy (PML) followi
90 e of the central nervous system (CNS) called Progressive Multifocal Leukoencephalopathy (PML) in immu
91 ive agent of the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML) in immu
92 (Tysabri) was associated with a few cases of progressive multifocal leukoencephalopathy (PML) in mult
93 iomarkers associated with the development of progressive multifocal leukoencephalopathy (PML) in mult
95 velopment of the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML) in pati
97 us (JCV) seropositivity is a risk factor for progressive multifocal leukoencephalopathy (PML) in pati
98 des the laboratory confirmatory diagnosis of progressive multifocal leukoencephalopathy (PML) in pati
99 nd can cause the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML) in the
125 itors of this process.IMPORTANCE The disease progressive multifocal leukoencephalopathy (PML) is caus
127 ry syndrome (IRIS) in natalizumab-associated progressive multifocal leukoencephalopathy (PML) is of c
129 a result of immunocompromise and manifest as progressive multifocal leukoencephalopathy (PML) or gran
130 asma, and cerebrospinal fluid [CSF]) from 19 progressive multifocal leukoencephalopathy (PML) patient
131 n latent JC polyomavirus (JCV) infection and progressive multifocal leukoencephalopathy (PML) remains
132 ic agent of the human demyelinating disease, progressive multifocal leukoencephalopathy (PML) seen in
134 rstitial nephritis in primary infections and progressive multifocal leukoencephalopathy (PML) upon re
135 magnetic resonance imaging of the brain, and progressive multifocal leukoencephalopathy (PML) was ult
139 ppressed patients, JCV infection can lead to progressive multifocal leukoencephalopathy (PML), a fata
141 nsplant recipients are at risk of developing progressive multifocal leukoencephalopathy (PML), a rare
142 olyomavirus JC (JCV), the etiologic agent of progressive multifocal leukoencephalopathy (PML), an acq
143 of a patient with multiple sclerosis in whom progressive multifocal leukoencephalopathy (PML), an opp
144 Major concerns regard the risk of developing progressive multifocal leukoencephalopathy (PML), and th
147 ent of the fatal human demyelinating disease progressive multifocal leukoencephalopathy (PML), is an
148 s) known to be associated with CD treatment (progressive multifocal leukoencephalopathy (PML), seriou
149 actors affecting survival after diagnosis of progressive multifocal leukoencephalopathy (PML), we ana
150 stently found in the brains of patients with progressive multifocal leukoencephalopathy (PML), wherea
151 ive agent of the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML), which
174 tumors [lymphomas and gliomas] and two with progressive multifocal leukoencephalopathy [PML]) with t
175 lesion fraction was significantly greater in progressive multifocal leukoencephalopathy progressors t
177 ide, both of which induce degradation of the progressive multifocal leukoencephalopathy/retinoic acid
178 r SV40 distribution in classic demyelinating progressive multifocal leukoencephalopathy, some of the
181 cts of Tecfidera and its rare side effect of progressive multifocal leukoencephalopathy, we conducted
182 y virus (HIV) infection and biopsy-confirmed progressive multifocal leukoencephalopathy were randomly
183 opathy; lymphoma, hepatic encephalopathy and progressive multifocal leukoencephalopathy were seen mor
184 virus JC virus (JCV) is a causative agent of progressive multifocal leukoencephalopathy which results
185 ic agent of the fatal demyelinating disease, progressive multifocal leukoencephalopathy, which usuall
186 the prognosis of HIV-infected patients with progressive multifocal leukoencephalopathy who are treat
187 No reliable treatment options are known for progressive multifocal leukoencephalopathy with underlyi
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。